Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of Alberta
$60,000.00
vestigating breast cancer organoids
FY 2021-22
Summary
Breast cancer is the most prevalent cancer in women. First-line treatment for breast cancer includes surgery, with or without different regimens of chemotherapy and/or radiotherapy. Targeted hormone therapy or anti-HER2 therapy are available to the ER/PR+ and HER2+ breast cancer subtypes. Precision medicine is defined as clinical management tailored to the individual. An emerging model that has the potential to functionally predict personalized clinical response, is the patient-derived-organoid (PDO). PDOs are generated from an individual tumor and can be cultured in the laboratory as 3-dimensional organoids. Remarkably, these PDOs retain features of the original tumor, are stable over extended periods and are amenable to assessing drug sensitivity. PDOs could become a valuable tool to guide personalized treatment. For PDO-testing to become standard-of-care, there should be sufficient evidence demonstrating predictive value. Further, PDOs provide incredible windows to tackle clinical challenges, such as chemotherapy resistance. In this study, we will test whether PDO treatment response mimics patient response in the neoadjuvant setting. We will also use PDOs to identify mechanisms of chemotherapy resistance and test potential treatments. The success of our overall project will be a major accomplishment for any future intentions to use PDOs as clinical tools for personalized medicine.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
468135
Name
Goping Ing Swie M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
vestigating breast cancer organoids
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer; Chemotherapy And Radiotherapy
; Tumour Progression And Metastasis
Abstract
Breast cancer is the most prevalent cancer in women. First-line treatment for breast cancer includes surgery, with or without different regimens of chemotherapy and/or radiotherapy. Targeted hormone therapy or anti-HER2 therapy are available to the ER/PR+ and HER2+ breast cancer subtypes. Precision medicine is defined as clinical management tailored to the individual. An emerging model that has the potential to functionally predict personalized clinical response, is the patient-derived-organoid (PDO). PDOs are generated from an individual tumor and can be cultured in the laboratory as 3-dimensional organoids. Remarkably, these PDOs retain features of the original tumor, are stable over extended periods and are amenable to assessing drug sensitivity. PDOs could become a valuable tool to guide personalized treatment. For PDO-testing to become standard-of-care, there should be sufficient evidence demonstrating predictive value. Further, PDOs provide incredible windows to tackle clinical challenges, such as chemotherapy resistance. In this study, we will test whether PDO treatment response mimics patient response in the neoadjuvant setting. We will also use PDOs to identify mechanisms of chemotherapy resistance and test potential treatments. The success of our overall project will be a major accomplishment for any future intentions to use PDOs as clinical tools for personalized medicine.
Competitiondate
202202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Goping, Ing Swie M
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~